Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 4;12(2):417.
doi: 10.3390/jcm12020417.

Venous Thromboembolism and Bleeding after Transurethral Resection of the Prostate (TURP) in Patients with Preoperative Antithrombotic Therapy: A Single-Center Study from a Tertiary Hospital in China

Zhongyi Li  1 , Zhihuan Zheng  1 , Xuesong Liu  1 , Quan Zhu  1 , Kaixuan Li  1 , Li Huang  2 , Zhao Wang  1 , Zhengyan Tang  1
Affiliations

Venous Thromboembolism and Bleeding after Transurethral Resection of the Prostate (TURP) in Patients with Preoperative Antithrombotic Therapy: A Single-Center Study from a Tertiary Hospital in China

Zhongyi Li et al. J Clin Med. .

Abstract

Background: Venous thromboembolism (VTE) and postoperative hemorrhage are unavoidable complications of transurethral resection of the prostate (TURP). At present, more and more patients with benign prostate hyperplasia (BPH) need long-term antithrombotic therapy before operation due to cardiovascular diseases or cerebrovascular diseases. The purpose of this study was to investigate the effect of preoperative antithrombotic therapy history on lower extremity VTE and bleeding after TURP.

Methods: Patients who underwent TURP in the Department of Urology, Xiangya Hospital, Central South University, from January 2017 to December 2021 and took antithrombotic drugs before operation were retrospectively analyzed. The baseline data of patients were collected, including age, prostate volume, preoperative International Prostate Symptom Score (IPSS), complications, surgical history within one month, indications of preoperative antithrombotic drugs, drug types, medication duration, etc. Main outcome measures included venous thromboembolism after TURP, intraoperative and postoperative bleeding, and perioperative blood transfusion. Secondary outcome measures included operation duration and postoperative hospitalization days, the duration of stopping antithrombotic drugs before operation, the recovery time of antithrombotic drugs after operation, the condition of lower limbs within 3 months after operation, major adverse cardiac events (MACEs), and cerebrovascular complications and death.

Results: A total of 31 patients after TURP with a long preoperative history of antithrombotic drugs were included in this study. Six patients (19.4%) developed superficial venous thrombosis (SVT) postoperatively. Four of these patients progressed to deep vein thrombosis (DVT) without pulmonary thromboembolism (PE). Only one patient underwent extra bladder irrigation due to blockage of their urinary catheter by a blood clot postoperatively. The symptoms of hematuria mostly disappeared within one month postoperatively and lasted for up to three months postoperatively. No blood transfusion, surgical intervention to stop bleeding, lower limb discomfort such as swelling, MACEs, cerebrovascular complications, or death occurred in all patients within three months after surgery.

Conclusion: Short-term preoperative discontinuation may help patients with antithrombotic therapy to obtain a relatively safe opportunity for TURP surgery after professional evaluation of perioperative conditions. The risks of perioperative bleeding, VTE, and serious cardiovascular and cerebrovascular complications are relatively controllable. It is essential for urologists to pay more attention to the perioperative management of these patients. However, further high-quality research results are needed for more powerful verification.

Keywords: antithrombotic therapy; postoperative hemorrhage; transurethral resection of the prostate; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Rassweiler J., Teber D., Kuntz R., Hofmann R. Complications of Transurethral Resection of the Prostate (TURP)—Incidence, Management, and Prevention. Eur. Urol. 2006;50:969–979. doi: 10.1016/j.eururo.2005.12.042. Discussion 80. - DOI - PubMed
    1. Dornbier R., Pahouja G., Branch J., McVary K.T. The New American Urological Association Benign Prostatic Hyperplasia Clinical Guidelines: 2019 Update. Curr. Urol. Rep. 2020;21:32. doi: 10.1007/s11934-020-00985-0. - DOI - PubMed
    1. Mcvary K.T., Roehrborn C.G., Avins A.L., Barry M.J., Bruskewitz R.C., Donnell R.F., Foster H.E., Jr., Gonzalez C.M., Kaplan S.A., Penson D.F., et al. Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia. J. Urol. 2011;185:1793–1803. doi: 10.1016/j.juro.2011.01.074. - DOI - PubMed
    1. Oelke M., Bachmann A., Descazeaud A., Emberton M., Gravas S., Michel M.C., N’Dow J., Nordling J., de la Rosette J.J. EAU Guidelines on the Treatment and Follow-Up of Non-Neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. Eur. Urol. 2013;64:118–140. doi: 10.1016/j.eururo.2013.03.004. - DOI - PubMed
    1. Schulman S., Ageno W., Konstantinides S.V. Venous Thromboembolism: Past, Present and Future. Thromb. Haemost. 2017;117:1219–1229. doi: 10.1160/TH16-10-0823. - DOI - PubMed

LinkOut - more resources